Insulin-sensitizing agents have emerged as a cutting-edge therapy for both obese and non-obese PCOS phenotypes, especially those with underlying IR. This narrative review highlights the latest clinical studies to guide treatment strategies for women with PCOS and IR, with an emphasis on metformin. Here, INS is linked to polycystic ovary syndrome.